This page contains exclusive content for the member of the following sections: TTS, IXA, ITA. Log in to view.
Presenter: Florence , Lacaille, , France
Authors: Florence Lacaille1, Antonio Mellos1, Valerie Furlan2
Florence Lacaille1, Antonio Mellos1, Valerie Furlan2
1Pediatric Hepatogastroenterology-Nutrition, Hôpital Necker-Enfants malades, Paris, France; 2Pharmacy-Toxicology, Hôpital Bicêtre, Kremlin-Bicetre, France
Discussion.The average MP dose to achieve the target AUC is higher after ITx than after other organ Tx. Drug monitoring is recommended for the optimization of the MP dosage, early after introduction and regularly until the required exposure is achieved. Subsequently, MPA should be monitored when the immunosuppression is changed, a potentially interacting drug is introduced or withdrawn, in cases of worsened graft function, changes in serum albumin concentration, renal or liver function. The adequate dose for an individual patient is unpredictable, and cannot be extrapolated from the other organ Tx . A prospective trial should establish if the AUC0-12 therapeutic range of 30-60 mg/hour/L is associated with a reduced risk of rejection in ITx. Finally, larger studies are needed in order to determine if a limited sampling strategy, easier to perform, may be designed.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada